BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9001350)

  • 1. Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan.
    Katsumata N; Matsuno Y; Nakayama H; Takenaka T; Kobayashi Y; Takeyama K; Narabayashi M; Fukushima T; Yokozawa T; Nakata M; Tajima K; Ikeda H; Tobinai K
    Jpn J Clin Oncol; 1996 Dec; 26(6):445-54. PubMed ID: 9001350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical outcomes in low grade follicular lymphoma].
    Yamazaki T; Kura Y; Sato Y; Irie T; Kaneita Y; Mochimaru J; Hanai M; Yasukawa K; Sawada U; Horie T
    Rinsho Ketsueki; 1999 Jan; 40(1):1-8. PubMed ID: 10067089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of prognostic factors in follicular lymphoma patients.
    Kondo E; Ogura M; Kagami Y; Taji H; Miura K; Takeuchi T; Maeda S; Asakura S; Suzuki R; Nakamura S; Morishima Y
    Int J Hematol; 2001 Apr; 73(3):363-8. PubMed ID: 11345204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model.
    Romaguera JE; McLaughlin P; North L; Dixon D; Silvermintz KB; Garnsey LA; Velasquez WS; Hagemeister FB; Cabanillas F
    J Clin Oncol; 1991 May; 9(5):762-9. PubMed ID: 1707956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic factors of follicular lymphoma treated with combination chemotherapy].
    Niitsu N; Umeda M
    Rinsho Ketsueki; 1997 Jun; 38(6):496-504. PubMed ID: 9248325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
    Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
    PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment options have changed the survival of patients with follicular lymphoma.
    Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
    J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.
    Decaudin D; Lepage E; Brousse N; Brice P; Harousseau JL; Belhadj K; Tilly H; Michaux L; Chèze S; Coiffier B; Solal-Céligny P
    J Clin Oncol; 1999 Aug; 17(8):2499-505. PubMed ID: 10561315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M).
    Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ogawa M; Tominaga S; Tsugane S; Minato K
    Jpn J Clin Oncol; 1988 Jun; 18(2):113-24. PubMed ID: 3379782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.
    Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Ogawa M; Kimura I; Tominaga S
    J Clin Oncol; 1988 Jan; 6(1):128-41. PubMed ID: 2891797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
    Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
    Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
    J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases].
    Yang H; Lang RG; Liu FF; Wang XF; Jin ZJ; Lü AJ; Wang Y; Fu XL; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):79-84. PubMed ID: 21426801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage III follicular lymphoma: long-term follow-up and patterns of failure.
    Ha CS; Kong JS; McLaughlin P; Tucker SL; Fayad LE; Hess MA; Wilder RB; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):748-54. PubMed ID: 14529780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group.
    Anderson JR; Vose JM; Bierman PJ; Weisenberger DD; Sanger WG; Pierson J; Bast M; Armitage JO
    J Clin Oncol; 1993 Feb; 11(2):218-24. PubMed ID: 8426197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.